ILT7-Binding Protein for Autoimmune Disorder Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for autoimmune diseases, such as systemic lupus erythematosus (SLE) and discoid lupus erythematosus, are inadequate, with conventional immunosuppressant drugs causing significant side effects and failing to effectively prevent or treat these conditions.

Innovation Solution

Administration of a pharmaceutically effective amount of an immunoglobulin-like transcript 7 (ILT7)-binding protein, specifically an antibody comprising heavy and light chain Complementarity-Determining Regions, to reduce plasmacytoid dendritic cells (pDCs) and type I interferon gene signature (IFNGS) levels, thereby alleviating symptoms and improving renal and skin manifestations.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional immunosuppressant drugs are used to treat autoimmune diseases, then immune suppression is achieved, but significant side effects occur

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and targets the specific pathological mechanism driving autoimmune disease - the type I interferon axis and plasmacytoid dendritic cells (pDCs). By using anti-ILT7 antibodies to specifically deplete pDCs and block type I interferon signaling, the treatment achieves immune modulation without the broad immunosuppression that causes side effects in conventional therapies

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The treatment applies localized immune modulation by specifically targeting the type I interferon pathway and pDCs, rather than causing global immunosuppression. This selective approach affects only the pathological immune mechanisms while preserving normal immune function, thereby reducing side effects

Inventive Principle:

Principle #3Local quality

2Reliability

If conventional treatments are used for autoimmune diseases, then some symptom relief is achieved, but the diseases are not effectively prevented or treated

Engineering Contradiction:

Improvedisease prevention and treatmentVSAvoidautoreactive antibodies

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent employs preliminary action by depleting pDCs and blocking type I interferon signaling before autoreactive antibodies can accumulate and cause disease progression. By interfering with the type I interferon axis early in the pathogenic pathway, the treatment prevents the development of autoreactive antibodies and establishes immune tolerance

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent converts the harmful overactive type I interferon pathway into a therapeutic target. By using anti-ILT7 antibodies to block this pathway, the treatment transforms the disease-causing mechanism into a point of intervention, where the same pathway that generates autoreactive antibodies becomes the target for depletion and blockade, thereby preventing disease

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20240287176A1Methods of treatment of autoimmune disorders using ILT7 binding proteins

Publication Date: 2024.08.29 VIELA BIO INC

AI summary

The present disclosure is related to methods of treating an autoimmune disorder in a subject in need thereof comprising administering an immunoglobulin-like transcript 7 (ILT7) binding protein. The present disclosure also relates to methods of reducing plasmacytoid dendritic cells (pDCs), or reducing a type I interferon gene signature (IFNGS) in a tissue, of a subject in need thereof by administering an ILT7-binding protein to the subject.